Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 vs TPC in Metastatic Breast Cancer with Brain Metastases
NCT02915744Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2016
- Primary completion
- Jul 2020
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of etirinotecan pegol in breast cancer, sponsored by Nektar Therapeutics. Started Nov 2016; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02915744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915744.